Retacrit vs Epogen: Biosimilar Differences and Dosing

Retacrit (epoetin alfa-epbx) is a biosimilar version of Epogen (epoetin alfa), meaning they are not identical copies but are biologically and clinically equivalent for all approved uses. Both drugs stimulate red blood cell production to treat anemia, and the FDA approved Retacrit in 2018 as the first erythropoietin biosimilar available in the United States. The differences between them are subtle enough that clinical studies have consistently shown patients can switch from one to the other without any meaningful change in how well their anemia is managed.

What “Biosimilar” Actually Means Here

Epogen has been on the market since 1989 and is made from genetically engineered cells that produce a protein nearly identical to the erythropoietin your kidneys naturally make. That protein tells your bone marrow to ramp up red blood cell production. When a biologic drug like Epogen loses its market exclusivity, other manufacturers can develop their own version, but because biologics are made by living cells rather than simple chemical synthesis, no two manufacturing processes will produce a molecule that is atom-for-atom the same. The result is a biosimilar: a product that matches the reference drug closely enough in structure, function, and clinical outcomes to be considered therapeutically equivalent.

Retacrit went through that approval process. The FDA determined it was biosimilar to Epogen based on extensive structural comparison, animal studies, and clinical trials. In Europe, erythropoietin biosimilars have been approved and in use since 2007, giving regulators over a decade of real-world safety data before Retacrit reached the U.S. market.¹

How Close Are They at the Molecular Level

Because erythropoietin is a glycoprotein, meaning a protein decorated with sugar chains, the exact pattern of those sugars can vary between manufacturing processes. When researchers compared biosimilar and original epoetin products head to head using multiple laboratory methods, they found differences only at the level of certain sugar-bearing isoforms. Those structural variations, however, did not translate into any functional difference in lab or animal testing.² In other words, the molecules look slightly different under high-powered analysis, but they behave the same way when it matters.

An independent quality comparison that tested original products alongside biosimilars, including Retacrit, measured protein content, aggregation (clumping), isoform profiles, and potency in living animals. The study concluded that the biosimilars had the same or even better quality than the originals.³ That finding may surprise people who assume a lower-cost product must be a lower-quality product. In the case of erythropoietin biosimilars, the manufacturing processes are newer and sometimes produce a more consistent product.

Clinical Evidence for Switching Between the Two

The most practical question for patients already on Epogen is straightforward: what happens if your clinic switches you to Retacrit? A randomized trial specifically designed to answer that question enrolled adults on hemodialysis who were already receiving Epogen and either kept them on Epogen or switched them to Retacrit. Both groups followed the same dosing algorithm. The result was clear: switching to Retacrit was non-inferior to continuing Epogen in maintaining hemoglobin levels.⁴ “Non-inferior” is the regulatory standard for biosimilar switching studies; it means there was no detectable disadvantage to making the switch.

For patients, this matters because many dialysis centers have transitioned to Retacrit for cost reasons, and some patients worry that a change in product means a change in how well their anemia is controlled. The trial data suggests those concerns are unfounded when dosing is managed properly. Your hemoglobin targets, monitoring schedule, and dose adjustments stay the same regardless of which product you receive.

Approved Uses Are the Same

Retacrit carries the same FDA-approved indications as Epogen. Both are used to treat anemia caused by chronic kidney disease, whether you are on dialysis or not. Both are also approved for anemia caused by certain chemotherapy regimens in cancer patients. And both can be given before and after surgery to reduce the likelihood of needing a blood transfusion due to surgical blood loss.⁵

In oncology settings, real-world studies have confirmed that the biosimilar performs as expected. A study evaluating Retacrit’s use for chemotherapy-induced anemia in routine clinical practice found it was effective and well tolerated, including when iron supplementation was added alongside it.⁶ The broader clinical benefits associated with erythropoietin-stimulating agents, including increased exercise capacity, fewer transfusions, and improved quality of life, apply equally to both products.

Safety and the Immunogenicity Question

Whenever a biologic drug is injected, there is a small chance the immune system will recognize the protein as foreign and produce antibodies against it. With erythropoietin products, the worst-case scenario is a rare condition called pure red cell aplasia, or PRCA, where the body’s antibodies neutralize not just the drug but also the erythropoietin your own kidneys make. This effectively shuts down red blood cell production entirely. It happened at alarming rates in the early 2000s with one particular formulation of a reference erythropoietin product, and the memory of that episode has hung over biosimilar discussions ever since.⁷

The reassuring news is that real-world surveillance of erythropoietin biosimilars, including Retacrit’s European counterpart epoetin zeta, has shown PRCA rates far below that historical episode. A three-year observational study of subcutaneous epoetin zeta administration in patients with kidney-related anemia found only a single case of PRCA among thousands of patients, translating to a rate of roughly 0.84 per 10,000 patient-years. The study concluded there was no immunogenicity concern or new safety signal compared with what was already known about erythropoietin therapy.⁸

This does not mean immunogenicity monitoring is unnecessary. Because all biologics carry at least a theoretical risk that changes in manufacturing could affect immunogenic potential, regulatory agencies require ongoing pharmacovigilance for biosimilars just as they do for reference products. But there is no evidence that Retacrit carries a higher immune-related risk than Epogen.

Why Cost Drives the Conversation

Erythropoietin-stimulating agents are among the most expensive drugs in the dialysis population, and they have been for decades. For patients on hemodialysis who need injections multiple times per week, indefinitely, even modest per-dose savings compound into significant numbers over time. Biosimilars exist in large part to introduce price competition into markets where a single biologic manufacturer has dominated.

The FDA’s approval of Retacrit in 2018 was framed explicitly in terms of both clinical access and healthcare cost reduction. Before that approval, the U.S. erythropoietin market had no biosimilar competitors, even though Europe had them for over a decade.⁹ The degree of actual savings depends on how your insurance or dialysis provider negotiates pricing, so the out-of-pocket difference varies. Some patients pay nothing different because the cost is absorbed into a bundled dialysis payment. Others, particularly those with certain insurance structures, may see lower copays.

If your dialysis center switches from Epogen to Retacrit, the decision is almost always financially motivated. From a medical perspective, there is no clinical reason to prefer one over the other. The switch does not reflect a downgrade in your care.

Dosing and Administration Differences

In practical terms, the two products are dosed the same way. Both come as injectable solutions. Both can be given intravenously, which is the standard route during hemodialysis, or subcutaneously, which is more common for patients with chronic kidney disease who are not on dialysis and for cancer patients. The same hemoglobin targets and dose-adjustment guidelines apply to both.

One thing worth knowing: when patients are switched from Epogen to Retacrit, the starting dose of Retacrit is typically the same as the current Epogen dose. This is not like switching between two drugs in the same class where you might need to recalculate. The switching trial that demonstrated non-inferiority used a direct unit-for-unit conversion, with adjustments made the same way they would be for any patient whose hemoglobin drifts above or below target.¹⁰ If your dose changes after a switch, it is almost certainly because your hemoglobin level moved, not because the drug is weaker or stronger.

The Iron Factor

Both Retacrit and Epogen depend on adequate iron stores to work properly. Erythropoietin tells your bone marrow to make more red blood cells, but those cells need iron to build hemoglobin. If your iron is low, neither product will raise your hemoglobin effectively, and you may end up on escalating doses that still do not work well. This is true regardless of which erythropoietin product you are taking.

The oncology study that evaluated Retacrit in routine practice highlighted this interaction, finding that iron supplementation alongside the biosimilar contributed to its effectiveness for chemotherapy-induced anemia.¹¹ If you are switched from Epogen to Retacrit and your hemoglobin does not respond as expected, iron status is usually the first thing to check, not a problem with the biosimilar itself.

What About Children

Erythropoietin-stimulating agents are used in children with chronic kidney disease, though the evidence base is smaller than for adults. Pediatric studies have generally compared different erythropoietin products or dosing schedules and found similar effectiveness. In one trial of 124 children, switching between erythropoietin and a longer-acting agent produced equivalent hemoglobin changes over 28 weeks. A separate study of 114 children who had never received erythropoietin-stimulating agents compared weekly and every-other-week dosing and found both reached target hemoglobin in roughly the same timeframe.¹²

The pediatric data does not specifically pit Retacrit against Epogen in a head-to-head trial in children. But because the biosimilar approval pathway relies on demonstrating equivalence to the reference product in adults, regulatory agencies extend the approval to the same pediatric indications covered by the reference drug. If your child is prescribed Retacrit rather than Epogen, it is supported by the same equivalence rationale that applies to adults.

The Surgical Setting

Outside of kidney disease and cancer treatment, both Retacrit and Epogen are approved for a more niche indication: reducing the need for blood transfusions in patients scheduled for certain surgeries that carry a high risk of blood loss. The idea is to boost your red blood cell count before the operation so that if you lose blood during surgery, you are starting from a higher baseline and less likely to need donor blood.¹³

This use is less common than the kidney disease and oncology indications, partly because there are other strategies for blood conservation during surgery, including cell salvage and controlled blood pressure techniques. But when erythropoietin is used in this setting, the choice between Retacrit and Epogen is again a cost and availability decision, not a clinical one. The drug does the same thing regardless of which label is on the vial.

Why Some Clinicians Still Hesitate

Despite the evidence, some physicians remain cautious about biosimilars in general. This is not unique to erythropoietin products. Across therapeutic areas, surveys of healthcare professionals reveal lingering uncertainty about whether biosimilars are truly interchangeable with their reference products. Some of that hesitation traces back to the immunogenicity concerns described earlier: the memory of the early 2000s PRCA episodes with erythropoietin products left a lasting impression, particularly among nephrologists who lived through it.¹⁴

There is also a natural conservatism in medicine: if a patient is doing well on a particular drug, changing it feels like introducing unnecessary risk, even when the data says otherwise. For patients, the practical takeaway is that if your doctor expresses a preference for Epogen over Retacrit, it is worth asking whether that preference is based on clinical evidence or general caution about biosimilars. The published switching data specifically addresses the concern about changing products mid-treatment, and the results consistently show it is safe.

How Storage and Handling Compare

Both Retacrit and Epogen need to be refrigerated and protected from light. Neither should be frozen or shaken vigorously, as the protein can denature or aggregate, potentially reducing its effectiveness or, in theory, increasing immunogenic risk. If you self-inject at home, the handling instructions for Retacrit mirror those for Epogen. The prefilled syringes look different in packaging and labeling, but the actual storage and preparation steps are functionally the same.

One practical difference patients sometimes notice is the syringe design itself. Different manufacturers use different prefilled syringe formats, which can feel unfamiliar if you have been using one product for years. If you have difficulty with the new format after a switch, your care team can walk you through it. This is a packaging difference, not a drug difference.